Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05472948
Other study ID # GIHSYSU-23
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date February 1, 2023
Est. completion date November 30, 2025

Study information

Verified date February 2023
Source Sun Yat-sen University
Contact Yanhong Deng, Ph.D
Phone 86-13925106525
Email 13925106525@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To explore the safety and efficacy of Surufatinib and Sintilimab in Combination With Capecitabine in Patients With Previously Treated Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma : a Single-arm, a Single-center , Phase 2 Trial. Meanwhile, Exploring the maximum tolerant dose or recommended II research dose of Surufatinib combined with a fixed dose of Sintilimab and Capecitabine using 3 + 3 dose climbing experiment.


Recruitment information / eligibility

Status Recruiting
Enrollment 36
Est. completion date November 30, 2025
Est. primary completion date November 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Histological or cytological documentation of adenocarcinoma of Small Intestine or Appendix Carcinoma. All other histological types are excluded. 2. Subjects with metastatic adenocarcinoma of Small Intestine or Appendix Carcinoma. 3. Subjects must have failed at least one line of prior treatment. 4. Progression during or within 3 months following the last administration of approved standard therapies . 4.1 Subjects an adjuvant setting should have progressed during or within 6 months of completion of adjuvant therapy. 4.2 Subjects who have withdrawn from standard treatment due to unacceptable toxicity warranting discontinuation of treatment and precluding retreatment with the same agent prior to progression of disease will also be allowed into the study. 4.3 Subjects may have received prior treatment with Avastin (bevacizumab) 5. Subjects must have measurable or non measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria, version 1.1. 6. Eastern Cooperative Oncology Group (ECOG) Performance Status of 1. 7. Life expectancy of at least 3 months. 8. Adequate bone marrow, liver and renal function as assessed by the laboratory required by protocol. Exclusion Criteria: 1. Prior treatment with Surufatinib 2. Previously received anti-programmed death-1 (PD-1) or its ligand (PD-L1) antibody, anti-cytotoxic T lymphocyte-associated antigen 4 (cytotoxic T- lymphocyte-associated Protein 4, CTLA-4) antibody or other drug/antibody that acts on T cell costimulation or checkpoint pathways. 3. Previous or concurrent cancer that is distinct in primary site or histology from colorectal cancer within 5 years prior to randomization EXCEPT for curatively treated cervical cancer in situ, non-melanoma skin cancer and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor invades lamina propria)]. 4. Cardiological disease including Congestive heart failure, Unstable angina, Myocardial infarction, Cardiac arrhythmias requiring anti-arrhythmic therapy. 5. Uncontrolled hypertension. (Systolic blood pressure 150 mmHg or diastolic pressure 90 mmHg despite optimal medical management). 6. Pleural effusion or ascites that causes respiratory compromise. Arterial or venous thrombotic or embolic events. 7. Any history of or currently known brain metastases. 8. Interstitial lung disease with ongoing signs and symptoms at the time of informed consent. 9. Systemic anticancer therapy including cytotoxic therapy, signal transduction inhibitors, immunotherapy, and hormonal therapy during this trial or within 4 week.

Study Design


Intervention

Drug:
Surufatinib
Surufatinib will be given 200/250 mg po. qd.
Sintilimab
Sintilimab administered IV at a dose of 200mg every 3 weeks.
Capecitabine
Capecitabine will be given 2 weeks on/1 week off (1000 mg/m2 BID po.)

Locations

Country Name City State
China The Sixth Affiliated Hospital of Sun Yat-sen University Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-free survival (PFS) The PFS is defined as the time from the start of treatment to the date of first documented PD or death as a result of any cause, whichever occurred first. When a patient was alive and without progression, PFS was censored at the date of the last disease assessment. 2 year
Secondary Objective response rate (ORR) The percentage of subjects with total number of Complete Response (CR) + total number of Partial Response (PR). 2 year
Secondary Overall Survival (OS) OS is defined as the time from date of randomization to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact. 2 year
Secondary Disease Control Rate (DCR) DCR is defined as the percentage of subjects whose best response was not Progressive Disease (PD) according to Response Evaluation Criteria in Solid Tumors (RECIST) (= total number of Complete Response (CR) + total number of Partial Response (PR) + total number of Stable Disease (SD); CR, PR, or SD had to be maintained for at least 28 days from the first demonstration of that rating) 2 year
Secondary Safety variables (Incidence of Adverse Events [Safety and Tolerability]) Safety variables will be summarized using descriptive statistics based on adverse events collection 2 year
See also
  Status Clinical Trial Phase
Recruiting NCT04333706 - A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER) Phase 1/Phase 2
Withdrawn NCT05730673 - Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer Phase 2
Completed NCT01703585 - Feasibility Study of Genomic Profiling Methods and Timing in Tumor Samples
Completed NCT01216345 - Cetuximab + Gemox in Biliary Tract Cancer Phase 2
Recruiting NCT00509964 - Second-Line Irinotecan vs. ILF for AGC Phase 2
Active, not recruiting NCT02069730 - A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes N/A
Completed NCT01745757 - Cohort Study of Prospective Validation of Predictive Factors and Biological Imaging of Response to Bevacizumab and Paclitaxel in Patients With Metastatic Breast Cancer
Completed NCT01633645 - Bortezomib in Combination With Gemcitabine and Cisplatin in Advanced or Metastatic Non-Small Cell Lung Cancer Phase 2
Withdrawn NCT04602117 - ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer Phase 1
Recruiting NCT05496686 - Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma Phase 1
Completed NCT02639026 - Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers Phase 1
Completed NCT01719744 - Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma Phase 2
Recruiting NCT05673811 - Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer Phase 2
Recruiting NCT05868226 - PRE-I-SPY Phase I/Ib Oncology Platform Program Phase 1
Completed NCT00498797 - E3-Hormone Refractory Prostrate Cancer Taxotere Combination Phase 2
Completed NCT00507091 - Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination Phase 1
Recruiting NCT06007937 - A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer Phase 1/Phase 2
Completed NCT01974752 - Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) Phase 3